1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Senzime AB (publ)

Senzime AB (publ)

SEZI.ST
Senzime AB (publ)SE flagStockholm Stock Exchange
4.30
SEK
-0.02
- -
676.02MMarket Cap
Senzime AB (publ)
SEZI.ST
(Stockholm Stock Exchange)

Recent

price

4.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.03
0.09
0.04
0.01
0.06
- -
0.07
0.13
0.16
0.17
0.21
0.39
0.48
0.71
0.62
Revenue per Share
-0.32
-0.23
-0.38
-0.43
-0.43
-0.49
-0.33
-0.33
-0.54
-0.64
-0.83
-1.3
-1.99
-1.45
-0.97
-0.93
-0.97
Basic EPS, GAAP
-0.7
-0.54
-0.66
-0.51
-0.47
-0.7
-0.59
-0.56
-0.6
-0.6
-0.68
-1.33
-2.13
-1.32
-1.03
-0.86
-0.96
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.6
1.69
0.77
0.67
0.17
0.49
0.16
-1.69
-2.01
-2.4
-2.95
-3.92
-5.69
-5.49
-5.09
-5.14
-5.25
Book Value per Share
-0.19
0.16
0.43
0.8
1.06
0.89
-0.46
-0.21
0.28
0.32
2.62
1.21
0.28
1.61
0.77
0.58
1.1
Tangible Book Value per Share
7
9
12
13
15
15
28
40
45
51
57
63
67
92
122
147
131
Basic Weighted Avg Shares
- -
- -
- -
1
1
- -
2
- -
3
7
9
11
14
36
58
104
81
Sales/Revenue/Turnover
- -
- -
-1,481.53
-463.39
-1,163.68
-4,965.36
-578.07
-6,891.53
-767.05
-508.39
-505.84
-774.86
-982.73
-374.07
-224.3
-115.3
-148.34
Operating Margin (%)
- -
- -
1
1
1
1
1
- -
4
11
12
11
16
21
26
24
27
Depreciation Expense
-2
-2
-4
-6
-6
-8
-9
-13
-24
-33
-47
-82
-133
-134
-119
-137
-126
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-1,472.37
-455.86
-1,144.16
-4,954.25
-578.13
-6,892.59
-749.07
-487.53
-508.13
-748.11
-945.56
-375.2
-203.03
-132.11
-156.76
Profit Margin (%)
1
2
5
11
15
14
8
6
27
29
159
84
37
163
110
94
154
Working Capital
3
- -
- -
- -
- -
- -
- -
1
- -
- -
1
1
11
9
19
12
13
LT Debt
22
28
32
37
44
46
132
84
112
110
231
151
262
375
346
304
371
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-23.08
-15.4
-36.05
-64.17
-110.45
-150.46
-155.74
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
4
4
2
LT Borrowings
- -
- -
- -
LT Finance Leases
19
18
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
133
133
157
Market Capitalization
673
592
681

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
148
117
184
Cash, Cash Equivalents & STI
101
62
132
Accounts Receivable, Net
10
16
13
Inventories
28
30
31
Total Current Liabilities
38
34
30
Payables & Accruals
- -
- -
- -
ST Debt
4
4
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.6%
12.5%
-11.97%
Free Cash Flow
32.6%
35.32%
0.72%
Net Income, GAAP
36.83%
28%
15.74%
Sales/Revenue/Turnover
296.57%
68.32%
77.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
15
17
14
58
2025
23
26
28
- -
104
2026
23
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.23
-0.28
-0.26
-0.2
-0.97
2025
-0.26
-0.24
-0.27
- -
-0.93
2026
-0.14
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Autonomix Medical, Inc. (AMIX)
Rapid Micro Biosystems, Inc. (RPID)
Escalon Medical Corp. (ESMC)
Vincent Medical Holdings Limited (1612.HK)
Carlsmed, Inc. (CARL)
Shanghai General Healthy Information and Technology Co., Ltd. (605186.SS)
Business
Senzime AB (publ) is a medical technology company specializing in developing and commercializing advanced monitoring solutions for patient safety in perioperative care and critical care environments. The company's core products include the Root® monitoring platform and associated disposable sensors, designed to facilitate real-time monitoring of vital signs, oxygen levels, and neuromuscular function; these products support anesthesiologists and critical care providers in managing patient care more effectively. Senzime offers a range of proprietary disposable sensors and software solutions that integrate with the Root® system, enhancing clinical decision-making through data-driven insights. The company operates primarily in the European market but is expanding globally through strategic partnerships and distribution agreements. Founded in 2009 and headquartered in Lund, Sweden, Senzime focuses on innovative healthcare solutions that improve patient outcomes and safety. Recent company developments include strategic collaborations with healthcare providers and distributors to expand its market reach, alongside ongoing efforts to launch new disposable sensor variants and software updates that enhance the Root® platform's functionality. These initiatives align with Senzime's strategic ambition to broaden its footprint in critical care and perioperative monitoring segments. The company's business segments encompass medical devices for monitoring, services related to training and support, and ongoing R&D activities to introduce next-generation monitoring technologies. Senzime continually strengthens its presence through targeted acquisitions, funding rounds, and technological enhancements to maintain a competitive edge in the medical technology industry.

Company News

APIChatGPT

  • accessnewswire.com

    Senzime Unveils the Next Set of Innovations in Neuromuscular Monitoring With the Launch of EMGINE Sirius

  • accessnewswire.com

    Senzime Secures Major TetraGraph Order from Leading UK NHS Hospital System